Stereotaxis Inc (STXS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • AMEX
Market Cap: $85.02M
Last updated: Nov 17, 2026 at 11:05 AM ET
Stereotaxis Inc (STXS) Stock Forecast
Analysts expect Stereotaxis (STXS) to earn -$0.22 per share in the fiscal year ending Dec 31, 2026, on revenue of $31.90M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 1.67, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 2 | 66.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 35.4%.
- Fiscal year ending Dec 31, 2026
- -$0.22
- EPS consensus, revenue $31.90M
- Fiscal year ending Dec 31, 2027
- -$0.17
- EPS consensus, revenue $43.20M
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.22 to -$0.22 | 1 | $31.90M | $30.90M to $32.80M | 3 |
| Dec 31, 2027 | -$0.17 | -$0.17 to -$0.17 | 1 | $43.20M | $42.50M to $44.00M | 3 |
Quarterly Estimates
The EPS consensus rises from -$0.05 for the quarter ending Dec 31, 2026 to -$0.02 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.05 | -$0.05 to -$0.04 | 5 | $8.91M | $7.84M to $9.55M | 5 |
| Mar 31, 2027 | -$0.02 | -$0.02 to -$0.02 | 1 | $9.50M | $9.50M to $9.50M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.22 | -$0.21 | -$0.21 | -$0.21 | -$0.21 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.17 | -$0.16 | -$0.16 | -$0.16 | -$0.16 | N/A |
| Quarter ending Mar 31, 2027 | -$0.02 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | N/A |
Frequently Asked Questions About STXS
What is the STXS stock forecast?
Consensus analyst estimates put Stereotaxis's EPS at -$0.22 for the fiscal year ending Dec 31, 2026, on revenue of $31.90M. The consensus rating from 3 analysts is Buy.
How do analysts rate STXS stock?
Of 3 analysts covering Stereotaxis, 1 rates it Strong Buy, 2 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from STXS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.22, with estimates from -$0.22 to -$0.22 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.17, with estimates from -$0.17 to -$0.17 from 1 analyst.
What revenue do analysts expect from Stereotaxis next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $31.90M, with estimates from $30.90M to $32.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $43.20M, with estimates from $42.50M to $44.00M.
How many analysts cover STXS?
3 analysts rate Stereotaxis stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
STXS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors